Statement of purpose: Malaria still exists as a serious global health issues despite extensive measures to eradicate the disease and prevent the spread. This infection is caused by Plasmodium parasites. There were an estimated 216 million infections and a death toll of 445, 000 in 2016 (WHO). Primaquine (PQ), an 8-aminoquinoline antimalarial is widely used to treat both liver stage infection and blood parasites, and is the only FDA approved drug for the prevention of hypnozoite stage of P. vivax and P. ovale and stage V gametocyte of P. falciparum. However, the downside is that the 14-day dosing regimen necessitated by its short elimination half-life (3~6 h) poses a high risk for hemolytic anemia in individuals with genetic deficiency in glucose-6-phosphate dehydrogenase (G6PD), and this limits the therapeutic index of PQ in public health settings. To reduce the mass drug administration and associated toxicity, we have designed long acting controlled delivery materials (drugamers) to specifically deliver PQ to the liver hepatocytes and minimize blood PQ exposure levels.